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Vestibular schwannoma: role of conservative management
R SURYANARAYANAN, R T RAMSDEN, S R SAEED*, R AGGARWAL, A T KING†, S A RUTHERFORD†,
D G EVANS‡, J E GILLESPIE**
Abstract
Objective: To assess the outcome of conservative management of vestibular schwannoma.
Study design: Observational study.
Setting: Tertiary referral centre.
Patients: Four hundred and thirty-six patients with vestibular schwannoma (490 tumours), including 327
sporadic tumours and 163 tumours in 109 patients with neurofibromatosis type two.
Main outcome measures: The relationship of tumour growth to tumour size at presentation, and to
certain demographic features.
Results: The initial tumour size was significantly larger in the neurofibromatosis type two group (11 mm)
than in the sporadic vestibular schwannoma group (5.1 mm). In both groups, 68 per cent of tumours did not
grow during follow up (mean 3.6 years; range one to 14 years). The mean growth rate was 1.1 mm/year
(range 0–15 mm/year) for sporadic tumours and 1.7 mm/year (range 0–18 mm/year) for
neurofibromatosis type two tumours. The tumour growth rate correlated positively with tumour size in
the sporadic tumour group, and correlated negatively with age in the neurofibromatosis type two group.
Conclusion: Two-thirds of vestibular schwannomas did not grow. Radiological surveillance is an
acceptable approach in carefully selected patients. Once a sporadic vestibular schwannoma reaches
2 cm in intracranial diameter, it is likely to continue growing. We do not recommend conservative
management for sporadic tumours with an intracranial diameter of 1.5 cm or more. Vestibular
schwannoma management is more complex in patients with neurofibromatosis type two.
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Introduction
The management of vestibular schwannoma has
evolved over time. Surgery was the popular choice
in earlier days, due to late diagnosis and large
tumour size at presentation. Non-surgical treatment
was not entertained as an option. The advent of com-
puted tomography and the more accurate modality of
magnetic resonance imaging (MRI) enabled a new
management approach of ‘wait and rescan’, because
of these imaging modalities’ ability to detect
smaller tumours. The majority of vestibular schwan-
nomas may never grow, within the patient’s lifespan,
to a size requiring treatment, a fact supported by
cadaveric studies showing a vestibular schwannoma
incidence of 0.6–0.9 per cent. Stereotactic radiosur-
gery has enabled a third management option for
growing tumours, depending on the patient’s wishes
and general fitness and the tumour size. Neverthe-
less, surgery continues to play a crucial role in the
treatment of patients with larger or growing tumours.
Over time, the clinician’s perspective has changed,
and the treatment goal has shifted from complete
tumour removal to preservation of hearing and
facial nerve function.
Now, if patients’ schwannomas are diagnosed suffi-
ciently early, all three management options can be
offered. In order to counsel correctly patients with
small tumours, the clinician must select the best man-
agement in each case. It would be ideal if clinicians
could predict which tumours will grow and which will
not. A better understanding of the growth pattern of
vestibular schwannomas would assist such decision-
making. If the growth rate could be predicted pre-
operatively, this may improve selection of surgical
candidates. Several studies have addressed this issue.
We wish to add to this enquiry information on ves-
tibular schwannoma behaviour derived from our own
patient series.
Materials and methods
Study design
This study was based mainly on data collected and
maintained by the senior author (RTR). From this
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data, the following details were extracted: patient age
and sex; initial tumour size; change in tumour size at
follow up; reasons for conservative management; and
outcome. We analysed separately sporadic vestibular
schwannomas and those occurring as part of neurofi-
bromatosis type two (NF2).
Inclusion criteria
We included in the study patients with vestibular
schwannoma who were initially managed by radio-
logical surveillance using serial (usually annual)
MRI scans.
Exclusion criteria
Patients were excluded if they had cerebellopontine
angle tumours other than vestibular schwannoma,
or if they had undergone previous surgery or radi-
ation therapy. No sporadic vestibular schwannoma
with an intracranial diameter greater than 2 cm was
included in the study, as it was already our policy
to recommend microsurgery or irradiation for
such tumours. There was no such exclusion for
NF2-associated vestibular schwannomas, as many
of these patients had large, unoperated tumours
which were managed conservatively in an attempt
to preserve hearing for as long as possible.
Outcome measures and variables
The tumour size recorded was the maximum tumour
dimension in the cerebellopontine angle (i.e. intra-
cranial), calculated on the basis of measurements
taken along the longest measurable distance on a
single image. This could be either the longest antero-
posterior or medio-lateral dimension. Patients with
intracanalicular tumours were classified separately
as the intrameatal group, and the size of these
tumours was described as 0 mm intracranial. The
tumour growth rate was calculated by noting the
change in tumour size between the initial scan and
the latest available scan and then dividing this
figure by the interval between the scans. Tumour
growth was defined as an increase in the maximum
tumour dimension of more than 1 mm along the
same axis on serial scans.
Statistical analysis
Statistical methods were used to evaluate separately
the growth rate and the frequency of growth in
sporadic and NF2 vestibular schwannomas. Pearson
correlation was used to study the association between
age, initial tumour size and growth rate. The Mann–
Whitney test was used to compare the median values
in different groups, as the data were non-parametric
in distribution. The criterion for statistical significance
was set at p, 0.05. The Kaplan–Meier method was
used to determine the probability of growth overall,
and to compare subgroups. The Statistical Package
for the Social Sciences version 16 software was used
for statistical analysis.
Results
Over a period of 29 years up to 2006, more than 1600
vestibular schwannomas have been managed in the
otolaryngology department of the Manchester
Royal Infirmary, UK. Up until 1992, every patient
referred with vestibular schwannoma underwent
surgery. Thereafter, conservative management
began to be adopted due to the advent of MRI, with
its ability to detect very small tumours (Figure 1).
Over the study period, 490 vestibular schwanno-
mas (in 436 patients) were selected for conservative
radiological surveillance. Of these, 327 were sporadic
tumours, whilst 163 tumours in 109 patients occurred
as part of NF2 (54 patients had bilateral tumours).
The follow-up period for these ‘wait and rescan’
patients varied from one to 14 years (mean 3.6
years; median 3.3 years). The mean age at presen-
tation was significantly higher in the sporadic group
than in the NF2 group (Table I). There was a slight
male preponderance in the sporadic group (1.17:1),
while the sex incidence was nearly equal in the NF2
group (1.03:1).
The mean and median initial tumour sizes
(Table I) were significantly larger in the NF2 group
compared with the sporadic group. The statistical sig-
nificance of the difference between the two medians
FIG. 1
Patients with vestibular schwannoma referred to and operated upon in our department, indicating the change in management policy
that occurred in 1992 (data available from 1978 to 2003).
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was p ¼ 0.001 (Mann–Whitney U test). Forty-seven
per cent of the sporadic tumours and 31 per cent of
the NF2 tumours were intracanalicular at presen-
tation. Patient age correlated negatively with initial
tumour size in the NF2 group (Pearson correlation
coefficient ¼ 20.220; p ¼ 0.028). There was no
significant correlation between patient age and
tumour size in the sporadic group. The tumours
were graded based on their initial size (Table II).
Reasons for pursuing a ‘watch and rescan’ man-
agement policy for sporadic tumours are given in
Table III. They included small tumour size, absence
of demonstrable growth, long duration of symptoms,
tumour involving the better hearing ear or only
hearing ear (e.g. in patients who had had a vestibular
schwannoma removed from the opposite ear), poor
medical history, and patient preference. In many
cases, two or more factors influenced the decision.
Of the 327 patients with sporadic tumours, 41 were
still awaiting their second scan at the time of analysis
and were thus excluded. Of the remaining 286
patients, 72 proceeded to treatment after a period
of watching (60 underwent microsurgery and 12
stereotactic radiosurgery). The commonest reason
to proceed to treatment was tumour growth, but
three patients preferred treatment even in the
absence of growth. Five patients were discharged
(two refused further scanning, two were in poor
health and one wished to be discharged). Eight
patients died of unrelated causes after a period of
watchful waiting. Nine patients were lost to follow
up. Follow-up records were unavailable for 11
patients. At the end of the study, 63 per cent of
patients with sporadic tumours (181 of 286) contin-
ued to remain under watchful waiting.
Of the 109 patients (163 tumours) in the NF2
group, five (seven tumours) were awaiting a second
scan at the time of analysis and were thus excluded.
Of the remaining 156 tumours, 45 were treated by
surgery and six by stereotactic radiotherapy. Four
patients (seven tumours) were lost to follow up.
One patient (two tumours) received treatment else-
where. Follow-up records were unavailable for
seven patients (10 tumours). At the end of the
study, 55 per cent of the NF2 tumours (86 of 156)
continued to remain under radiological surveillance.
Data on growth were available for 240 sporadic
tumours and 115 NF2 tumours (Table IV). The
majority of the tumours in both groups (68 per
cent) showed no change in tumour size over the
period of observation. However, nearly one-third of
the tumours in each group did demonstrate growth
during the follow-up period. All growing tumours
were identified within the first four years of follow
up. The initial size of the growing tumours ranged
from 0 mm (intracanalicular) to 20 mm in the spora-
dic group and from 0 mm (intracanalicular) to 50 mm
in the NF2 group. The initial tumour size of the static
tumours varied from 0 mm (intracanalicular) to
20 mm in the sporadic group and from 0 mm (intraca-
nalicular) to 40 mm in the NF2 group. In both the
sporadic and NF2 groups, growing tumours had a sig-
nificantly larger initial size compared with static
tumours (Table V). Figures 2 and 3 show the pro-
portion of growing tumours compared with initial
tumour size, for both groups. The proportion of
growing tumours tended to increase with tumour
grade in both groups. Kaplan–Meier survival
TABLE I
PATIENT DEMOGRAPHICS AND INITIAL VESTIBULAR SCHWANNOMA
SIZE
Parameter VS type
Sporadic NF2
Sex ratio 176:151 56:54
Mean age (y) 60.5 30.8
Age range (y) 20–85 7–70
Initial tumour size (mm)
Mean 5.1 11
Median 2.5 8.8
Range IC to 20 IC to 40
Male:female. VS ¼ vestibular schwannoma; NF2 ¼ neurofi-
bromatosis type two; y ¼ years; IC ¼ intracanalicular
TABLE III
REASONS FOR CONSERVATIVE MANAGEMENT OF THE SPORADIC
TUMOURS
Reason Tumours (%)
Small size 22
No growth 14
Long history 12
Better or only hearing ear 29
Patient preference 5
Co-morbidity 18
Minimal symptoms 5
TABLE IV
VESTIBULAR SCHWANNOMA GROWTH PATTERNS
Pattern VS type (n (%))
Sporadic NF2
Growth 74/240 (30) 37/115 (32)
No change 162/240 (68) 78/115 (68)
Regression 4/240 (2) 0
VS¼ vestibular schwannoma; NF2¼ neurofibromatosis type two
TABLE II
VESTIBULAR SCHWANNOMA GRADING BY INITIAL SIZE1
Grade VS type
Non-NF2 NF2
Intrameatal 155 50
Grade 1 (1–10 mm IC) 132 54
Grade 2 (11–20 mm IC) 34 28
Grade 3 (21–30 mm IC) 0 11
Grade 4 (31–40 mm IC) 0 7
Grade 5 (.40 mm IC) 0 4
All data represent tumour numbers. Maximum tumour
dimension. VS ¼ vestibular schwannoma; NF2 ¼ neurofibro-
matosis type two; IC ¼ intracranial
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analysis showed that the probability of tumour
growth was significantly higher for tumours with an
extracanalicular size of more than 15 mm (both
sporadic and NF2) (Figures 4 and 5). Kaplan–
Meier analysis also showed a higher probability of
growth for extracanalicular sporadic tumours than
intracanalicular ones (Figure 6). Four sporadic
tumours regressed in size; of these, one tumour had
an initial size of 5 mm and the remainder were
intrameatal.
The mean tumour growth rate was higher in the NF2
group compared with the sporadic group, but this
difference was not statistically significant (Table VI).
However, the growth rate was significantly higher
in tumours that required intervention than in those
that did not (Table VII). In the sporadic group, the
tumour growth rate correlated positively with the
initial tumour size (Pearson correlation coefficient¼
0.334; p ¼ 0.00). However, there was no such corre-
lation in the NF2 group. The growth rate correlated
negatively with patient age in the NF2 group
(Pearson correlation coefficient ¼ 20.287; p¼ 0.014).
No such correlation was found in the sporadic group.
In both groups, there was no correlation between
patient sex and tumour growth rate.
Twelve of the sporadic and six of the NF2 tumours
had a cystic tumour. Their initial size varied from
0 mm (intracanalicular) to 20 mm in the sporadic
group and 0 mm (intracanalicular) to 30 mm in the
NF2 group. Five tumours grew at a rate of 5 mm/year.
Patients’ overall mean pure tone average at presen-
tation was 47 dB, ranging from 0 dB to a ‘dead ear’.
Their speech discrimination scores varied from 0 to
100 per cent, with a mean of 55 per cent. The mean
pure tone average and speech discrimination score
were 52 dB and 48 per cent in the sporadic group
and 37 dB and 72 per cent in the NF2 group, respect-
ively. The initial tumour size did not correlate with
either the pure tone average or the maximum
speech discrimination score.
Discussion
Over the years, several attempts have been made to
understand the natural behaviour of vestibular
TABLE V
INITIAL SIZE OF GROWING AND STATIC VESTIBULAR SCHWANNOMAS
Size (mm) VS type p†
Growing Static
Sporadic
Mean (range) 6.8 (0–20) 4.6 (0–20)
Median 5 0 0.0123
NF2
Mean (range) 15.4 (0–50) 7.4 (0–40)
Median 15 5 0.0001
A value of 0 mm was given to intrameatal (intracanalicular)
tumours for statistical calculations. Maximum tumour dimen-
sion. †Mann–Whitney test. VS ¼ vestibular schwannoma;
NF2 ¼ neurofibromatosis type two
FIG. 2
Proportion of growing tumours versus initial size in
neurofibromatosis type two vestibular schwannoma group.
IC ¼ intracanalicular.
FIG. 3
Proportion of growing tumours versus initial size in sporadic
vestibular schwannoma group. IC ¼ intracanalicular.
FIG. 4
Kaplan–Meier curves for growth probability of sporadic
vestibular schwannomas with initial extracanalicular size
,15 mm versus . 15 mm, showing significant difference in ‘no
growth rate’ (log rank test: chi-square ¼ 18.1; p ¼ 0.00).
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schwannomas. The ideal way to identify the effect of
the various management modalities available (such
as radiological surveillance, surgery and radiother-
apy) would be to perform randomised, controlled
trials, but in reality this is difficult. For that reason,
the published literature contains no evidence better
than level three or four.2 At present, it appears that
the best available method of identifying the growth
characteristics of this tumour is a prospective study
using serial MRI scanning.3,4
Nearly two-thirds of our patients did not show any
change in their vestibular schwannoma size over
the study period. The reported proportion of
growing tumours varies from 43 to 54 per cent
(Table VIII).3,5–7 The mean annual growth rate ident-
ified by the studies shown in Table VIII varied from
1.2 to 1.9 mm/year; this is similar to our results for
the overall annual growth rate of sporadic tumours
(1.1 mm/year) as well as NF2 tumours (1.7 mm/year).
As one would expect, we found a higher vestibular
schwannoma growth rate in the NF2 group than in
the sporadic tumour group. Vestibular schwannoma
growth rates in NF2 are highly variable and tend
to decrease with increasing age.8 This may be due
in part to the fact that patients with slower growing
tumours are more likely to have a ‘benign’ phenotype
and are thus more likely to live to old age. Although
the decision to intervene is influenced by such factors
as patient choice, presence of co-morbidity, hearing
status and patient age, in our study tumour growth
appeared to be the main deciding factor, as demon-
strated by the significantly higher tumour growth
rate in the treated group.
We found that the vestibular schwannoma growth
rate correlated positively with the initial tumour
size in the sporadic group, and correlated negatively
with patient age in the NF2 group. We did not find
FIG. 5
Kaplan–Meier curves for growth probability of
neurofibromatosis type two vestibular schwannomas with
initial extracanalicular size ,15 mm versus .15 mm,
showing significant difference in ‘no growth rate’ (log rank
test: chi-square ¼ 7.5; p ¼ 0.006).
TABLE VI
VESTIBULAR SCHWANNOMA GROWTH RATES
VS type Mean Median Range
Sporadic 1.1 0 0–15
NF2 1.7 0 0–18
Data represent growth rates in mm/year. VS ¼ vestibular
schwannoma; NF2 ¼ neurofibromatosis type two
TABLE VII
ANNUAL VESTIBULAR SCHWANNOMA GROWTH RATE: TREATED VS
WATCHED TUMOURS
Growth rate (mm/y) Treated Watched p
Sporadic
Mean 4.8 0.18
Median 3.4 0 0.00
Range 0–15 0–4
NF2
Mean 5.8 0.5
Median 5.0 0 0.00
Range 0–18 0–11
Mann–Whitney test. Y ¼ year; NF2 ¼ neurofibromatosis
type two
FIG. 6
Kaplan–Meier curves for intracanalicular versus
extracanalicular sporadic vestibular schwannoma, showing
significant difference in ‘no growth rate’ (log rank test:
chi-square ¼ 5.2; p ¼ 0.023).
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any correlation with patient sex or symptom duration.
There is no consensus in the literature to assist the pre-
diction of growth based on information available at
presentation. Ogawa et al.9 found tumour growth to
be related to several factors such as age, sex and
tumour size. They found a higher tumour growth rate
in younger patients and those with larger tumours.
They also found that female patients had larger
tumours at presentation, and that their tumours grew
faster than those in male patients. Other authors
have also observed this tendency for increased
tumour growth in younger patients, but more so
in men than women.10–12 In contrast, Valvassori and
Guzman found no correlation between tumour
growth rate and patient age or length of follow up.13
In our patients with sporadic vestibular schwan-
noma, the initial tumour size did not correlate with
patient age, a finding also reported by Mirz et al.14
However we found that the initial tumour size corre-
lated positively with the tumour growth rate. We
demonstrated quite clearly that grade two tumours
grew faster than grade one tumours. Fucci et al.
described a similar finding: tumours initially larger
than 20 mm were more likely to grow than smaller
tumours.15 Further, Martin and colleagues’ ‘inten-
tion to treat’ analysis showed that conservative man-
agement of vestibular schwannomas with an
intracranial size of up to 20 mm was safe and
yielded significantly better preservation of facial
nerve function and hearing, compared with surgical
management.16 Intracanalicular tumours do not
exhibit significant growth, compared with tumours
with extension into the cerebellopontine angle.17
We found a significantly higher probability of
growth in vestibular schwannomas with an intracra-
nial size of more than 15 mm, in both the sporadic
and NF2 groups. Our findings have subsequently
influenced our management strategy for sporadic
vestibular schwannomas. We now discuss active man-
agement with all patients with tumours of 15 mm
intracranial diameter or more – usually microsur-
gery, or stereotactic radiosurgery in a minority.
This is in close agreement with the large Copenhagen
series of Charabi et al.18
These authors also found symptom duration to
have predictive value in identifying tumour growth,
but this has not been confirmed by our or any other
study. Tschudi et al. showed that patients with
progressive hearing loss as a first symptom had sig-
nificantly slower tumour growth than those presenting
with tinnitus, sudden hearing loss or dizziness.19
We found no correlation between tumour size at pres-
entation and hearing level. Some authors have found
positive growth during the first year of observation
to be predictive of future growth.12,19–21
Previous studies involving the senior author’s
patients concluded that the clinical features evident
at presentation and diagnosis have no power to
predict the expected behaviour of sporadic vestibu-
lar schwannoma.22,23 These studies also showed that
growth estimates based on clinical history have no pre-
dictive ability. Furthermore, sporadic vestibular
schwannoma has been shown to exhibit many differ-
ent growth patterns, such as: stability; initial growth
followed by stability; stability followed by regression;
stability followed by growth; continuous regression;
and continuous growth.19,24 It appears that the only
way to identify growing tumours is to follow them reg-
ularly with imaging.
. Conservative radiological surveillance is an
acceptable method of managing vestibular
schwannomas
. Growing tumours are identifiable within the
first five years of follow up
. Treatment should be offered to patients with
sporadic vestibular schwannomas with an
intracranial size exceeding 15 mm
. Decisions regarding management of
neurofibromatosis type two vestibular
schwannomas are more complex
Clinicians working in this field will be aware of just
how problematic decision-making can be for patients
suffering from NF2. Tumour behaviour varies enor-
mously depending on the genotype and phenotype
of the individual.25,26 Because of the bilateral
nature of the disease, there is often reluctance on
the part of the surgeon or the patient to consider
removing a tumour if there is still useful hearing on
that side, especially if the opposite ear is completely
deaf. For that reason, we are often prepared to
observe even grade four tumours until such time as
TABLE VIII
PREVIOUS REVIEWS OF VESTIBULAR SCHWANNOMA BEHAVIOUR AND CONSERVATIVE MANAGEMENT
Parameter Selesnick & Johnson5 Yoshimoto3 Smouha et al.6 Yamakami et al.7
Study type Meta-analysis Meta-analysis Meta-analysis Systematic review
Studies included (n) 13 26 21 13
Patients (n) 571 1340 1345 903
Mean age (y) 64 62 62 65
Mean follow up 3 y 38 mth 3.2 y 3.1 y
Mean tumour size (mm) 11.8 11 11.8 10
Mean tumour growth (mm/y) 1.8 1.2 1.9 1.87
Growing tumours (%) 54 46 43 51
Watched tumours needing treatment (%) 26 18 20 20
NF2 inclusion Included Excluded Included Included
Overall; prospective studies, 29%. Y ¼ years; mth ¼ months; NF2 ¼ neurofibromatosis type two
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hearing is lost naturally, or until removal becomes a
neurosurgical imperative.
We acknowledge that the outcome of conservative
management in our group of patients is in keeping
with other published series and holds no surprises.
However, the current study differs from several
others in its methodology. Most of the data on
growth were collected prospectively. In particular,
every tumour size measurement was performed by
the senior author (RTR) himself in the clinic,
thereby reducing inter-observer variability. In order
to maximise the identification of growing tumours,
we considered a change in dimension of 1 mm to be
significant, as opposed to many other published
studies which used a value of 2 mm or more. We
also followed the guidelines set out at the consensus
meeting on reporting the results of vestibular
schwannoma management, held in Tokyo in 2001.
We hope that future authors will also report their
results based on these guidelines, as this will assist
future meta-analysis.
Conclusion
In this study, two-thirds of patients’ vestibular schwan-
nomas showed no growth. Conservative management,
using serial scans, can be regarded as a safe approach in
carefully selected patients with vestibular schwan-
noma. Factors that influence the decision to rec-
ommend surgery include patient choice, general
health, hearing levels (in both the ipsilateral and con-
tralateral ears) and whether the patient has NF2. The
most important criterion, however, is the size of the
tumour at presentation. Once a sporadic vestibular
schwannoma reaches 15 mm (intracranial diameter),
it is likely to continue growing. As a result of this
study, we do not recommend conservative manage-
ment for sporadic tumours with an intracranial diam-
eter of 15 mm or more. There are different patterns
of tumour growth in NF2; for patients with this con-
dition, management decisions are more complex.
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